DERM NASDAQ
Credit Risk of going bust: higher than 70% of companies Debt: 15.4% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.14 (down 97%), Journey Medical Corporation would be worth roughly what it owes.
Total debt $25.5M against a stock market value of $140.0M.
Distance to default 3.43 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $15.3M (short-term plus half of long-term), stock volatility 69.5%; Altman Z 0.77. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Scottsdale, AZ 85258
US
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Toledano Miranda Jay | A-Award | 50,000 | — | 2026-07-01 |
| Smith Justin Adam | A-Award | 50,000 | — | 2026-07-01 |
| Herskowitz Neil | A-Award | 50,000 | — | 2026-07-01 |
| Toledano Miranda Jay | A-Award | 10,000 | — | 2026-06-25 |
| ROSENWALD LINDSAY A | A-Award | 10,000 | — | 2026-06-25 |